{
    "organizations": [],
    "uuid": "de4bf3dcbe1104ebac1f2a97a92b71e7330faa7c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-receives-us-pa/brief-mabvax-therapeutics-receives-u-s-patent-for-certain-fully-human-antibodies-idUSFWN1SO0PG",
    "ord_in_thread": 0,
    "title": "BRIEF-MabVax Therapeutics Receives U.S. Patent For Certain Fully Human Antibodies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 17 (Reuters) - MabVax Therapeutics Holdings Inc :\n* MABVAX THERAPEUTICS RECEIVES U.S. PATENT FOR FULLY HUMAN ANTIBODIES TARGETING THE ANTIGEN GD2 EXPRESSED ON SARCOMA, MELANOMA, AND NEUROBLASTOMA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T20:58:00.000+03:00",
    "crawled": "2018-05-18T19:51:27.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "mabvax",
        "therapeutic",
        "holding",
        "inc",
        "mabvax",
        "therapeutic",
        "receives",
        "patent",
        "fully",
        "human",
        "antibody",
        "targeting",
        "antigen",
        "gd2",
        "expressed",
        "sarcoma",
        "melanoma",
        "neuroblastoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}